Theranostic barcoded nanoparticles for personalized cancer medicine.
Personalized medicine promises to revolutionize cancer therapy by matching the most effective treatment to the individual patient. Using a nanoparticle-based system, we predict the therapeutic potency of anticancer medicines in a personalized manner. We carry out the diagnostic stage through a multidrug screen performed inside the tumour, extracting drug activity information with single cell sensitivity. By using 100 nm liposomes, loaded with various cancer drugs and corresponding synthetic DNA barcodes, we find a correlation between the cell viability and the drug it was exposed to, according to the matching barcodes. Based on this screen, we devise a treatment protocol for mice bearing triple-negative breast-cancer tumours, and its results confirm the diagnostic prediction. We show that the use of nanotechnology in cancer care is effective for generating personalized treatment protocols.
Department of Chemical Engineering, Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Technion-Israel Institute of Technology, Haifa 3200003, Israel.
Zvi
http://orcid.org/0000-0002-1889-1994
Z
Yaari
Department of Chemical Engineering, Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Technion-Israel Institute of Technology, Haifa 3200003, Israel.
Dana
D
da Silva
Department of Chemical Engineering, Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Technion-Israel Institute of Technology, Haifa 3200003, Israel.
Assaf
A
Zinger
Department of Chemical Engineering, Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Technion-Israel Institute of Technology, Haifa 3200003, Israel.
Evgeniya
E
Goldman
Department of Chemical Engineering, Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Technion-Israel Institute of Technology, Haifa 3200003, Israel.
Ashima
A
Kajal
Department of Chemical Engineering, Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Technion-Israel Institute of Technology, Haifa 3200003, Israel.
Rafi
R
Tshuva
Infrastructure Unit, Life Science and Engineering Center, Technion-Israel Institute of Technology, Haifa 3200003, Israel.
Efrat
E
Barak
Infrastructure Unit, Life Science and Engineering Center, Technion-Israel Institute of Technology, Haifa 3200003, Israel.
Nitsan
N
Dahan
Clinical Pathology Unit, Rambam Medical Center, Haifa 3525408, Israel.
Dov
D
Hershkovitz
Department of Chemical Engineering, Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Technion-Israel Institute of Technology, Haifa 3200003, Israel.
Mor
M
Goldfeder
Department of Chemical Engineering, Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Technion-Israel Institute of Technology, Haifa 3200003, Israel.
Janna Shainsky
JS
Roitman
Department of Chemical Engineering, Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Technion-Israel Institute of Technology, Haifa 3200003, Israel.
Avi
A
Schroeder
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use; D001483:Base Sequence; D045744:Cell Line, Tumor; D004247:DNA / Q000737:chemistry* / Q000235:genetics; D004337:Drug Carriers / Q000737:chemistry; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008807:Mice, Inbred BALB C; D053758:Nanoparticles / Q000737:chemistry* / Q000648:ultrastructure; D009369:Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics; D057285:Precision Medicine / Q000379:methods*; D000068936:Theranostic Nanomedicine / Q000379:methods*; D064726:Triple Negative Breast Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics
D000970:Antineoplastic Agents; D004337:Drug Carriers; D004247:DNA